⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56768 | 0.70 | TSHR (0.36) | — | |
| SCHEMBL8977293 | 0.65 | LMNA (0.31) | — | |
| SCHEMBL5024897 | 0.64 | — | — | |
| SCHEMBL4017065 | 0.61 | ALDH1A1 (0.38) | — | |
| SCHEMBL5260214 | 0.59 | SLC6A2 (0.31) | — | |
| SCHEMBL5703459 | 0.59 | SLC6A2 (0.31) | — | |
| SCHEMBL5262802 | 0.59 | SLC6A2 (0.31) | — | |
| SCHEMBL103453 | 0.59 | — | — | |
| SCHEMBL8903927 | 0.59 | — | — | |
| SCHEMBL4460224 | 0.59 | ALDH1A1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8277807-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-02 | — | — | US | claimed |
| EP-0039988-A1 | Apparatus for treating an intact animal organism bearing a neoplastic process and undergoing drug treatment | ELECTRO-BIOLOGY, INC (US) | 1981-11-18 | — | — | EP | claimed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-12030873-B2 | 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-07-09 | — | — | US | disclosed |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| US-20240166623-A1 | NOVEL PROCESS | ARTIOS PHARMA LIMITED (GB) | 2024-05-23 | — | — | US | disclosed |
| EP-2534153-B2 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO}METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE | PFIZER (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240131169-A1 | CLIPTAC COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| EP-4301875-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-01-10 | — | — | EP | disclosed |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| US-6653331-B2 | Depleting intracellular reduced glutathione levels in vivo | PHARMACIA & UPJOHN COMPANY | 2003-11-25 | — | — | US | disclosed |
| EP-0909184-B1 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | UPJOHN CO (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030109555-A1 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | PHARMACIA & UPJ0HN COMPANY | 2003-06-12 | — | — | US | disclosed |
| US-20030008923-A1 | Antineoplastic combinations | WYETH (US) | 2003-01-09 | — | — | US | disclosed |
| US-20020198137-A1 | Antineoplastic combinations | WYETH (US) | 2002-12-26 | — | — | US | disclosed |
| WO-2002098416-A2 | ANTINEOPLASTIC COMBINATIONS | WYETH (US) | 2002-12-12 | — | — | WO | disclosed |
| EP-0909184-A2 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 1999-04-21 | — | — | EP | disclosed |
| WO-1998000173-A2 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
| EP-0039988-A1 | Apparatus for treating an intact animal organism bearing a neoplastic process and undergoing drug treatment | ELECTRO-BIOLOGY, INC (US) | 1981-11-18 | — | — | EP | disclosed |